Biotech Research, Rare Disease Therapies, and Clinical Trials by Edgewise Therapeutics

  • Mykhailo Ihnatenko
  • 05.11.2026
Edgewise Therapeutics announces FDA End-of-Phase 2 meeting for EDG-7500: Will EWTX hold $36.81 support?
Edgewise Therapeutics announced the outcome of an End-of-Phase 2 meeting with the FDA for its EDG-7500 program in symptomatic hypertrophic cardiomyopathy. Separately, the stock edges lower on the ...
  • Viktoras Karapetjanc
  • 05.11.2026
Edgewise Therapeutics announces Q3 2026 financial results: Will EWTX hold $36.7 support?
Edgewise Therapeutics reported its financial results for the third quarter of 2026. The stock edges lower on the day, trading at $37.53.Edgewise Therapeutics announced its financial results for ...
  • Jose Antonio Gastelum
  • 06.08.2026
Edgewise Therapeutics stock rises after Q2 results and business update
Edgewise Therapeutics announced its financial results and business highlights for the second quarter of 2026. Even so, shares edge higher on the day, trading at $44.99.Edgewise Therapeutics ...
  • Andreas Kristo
  • 03.07.2026
Edgewise Therapeutics stock consolidates near key support as bullish momentum persists
Edgewise Therapeutics announced that its team is attending the International Congress on Neuromuscular Diseases in Florence, Italy.The company said it looks forward to connecting with leaders in ...
  • Andreas Kristo
  • 25.06.2026
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal
Edgewise Therapeutics will present the rationale, study design and baseline characteristics of its GRAND CANYON pivotal cohort at the 12th Congress of the European Academy of Neurology.The data ...
  • Emilio Ghigini
  • 24.06.2026
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event
Edgewise Therapeutics will participate in the 2026 BIO International Convention. The stock draws attention as its VP of Patient Advocacy, Abby Bronson, will speak at the event.Bronson will address ...